Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

被引：13

作者：

Zaja, Francesco ^{[1
,2
]}

Salvi, Flavia ^{[3
]}

Rossi, Maura ^{[4
]}

Sabattini, Elena ^{[5
]}

Evangelista, Andrea ^{[5
]}

Ciccone, Giovannino ^{[6
,7
]}

Angelucci, Emanuele ^{[8
]}

Gaidano, Gianluca ^{[9
]}

Zanni, Manuela ^{[9
]}

Ladetto, Marco ^{[3
]}

Chiappella, Annalisa ^{[10
]}

Vitolo, Umberto ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Califano, Catello ^{[12
]}

Tucci, Alessandra ^{[13
,14
]}

Patti, Caterina ^{[15
]}

Pileri, Stefano A. ^{[16
]}

Lenti, Valentina ^{[17
]}

Piccaluga, Pier Paolo ^{[4
]}

Cavallo, Federica ^{[18
]}

Volpetti, Stefano ^{[19
,20
]}

Perali, Giulia ^{[19
,20
]}

Assouline, Sarit ^{[21
]}

Mann, Koren Kathleen ^{[22
]}

Morin, Ryan ^{[23
]}

Alcaide, Miguel ^{[23
]}

Bushell, Kevin ^{[23
]}

Fanin, Renato ^{[1
,2
]}

Levis, Alessandro ^{[17
]}

机构：

[1] Univ Udine, Clin Ematol, DAME, Udine, Italy

[2] Univ Udine, Unita Terapie Cellulari Carlo Melzi, DAME, Udine, Italy

[3] AO SS Antonio & Biagio & C Arrigo, SC Ematol, Alessandria, Italy

[4] Univ Hosp Bologna, Unit Haemolymphopathol, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] Univ Hosp Bologna, Dept Hematol & Oncol, Unit Haemolymphopathol, Bologna, Italy

[6] AOU Citta Salute & Sci Torino, Unit Clin Epidemiol, Turin, Italy

[7] CPO Piemonte, Turin, Italy

[8] IRCCS AOU San Martino IST, UOC Ematol, Genoa, Italy

[9] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

[10] AOU Citta Salute & Sci, SC Ematol, Turin, Italy

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Osped Umberto I, UO Med Oncoematol, Nocera Inferiore, Italy

[13] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[14] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[15] Osped V Cervello, UOC Ematol, Palermo, Italy

[16] Milano Univ, Sch Med, European Inst Oncol, Haematopathol Unit, Bologna, Italy

[17] Fdn Italiana Linfomi, Alessandria, Italy

[18] Univ Torino, Azienda Osped Univ Citta Salute & Sci, Turin, Italy

[19] Azienda Sanit Univ Integrata, Clin Ematol, Udine, Italy

[20] Azienda Sanit Univ Integrata, Unita Terapie Cellulari Carlo Melzi, Udine, Italy

[21] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ, Canada

[22] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[23] Simon Fraser Univ, Dept Mol Biol & Biochem, Sch Comp Sci, Vancouver, BC, Canada

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 12期

关键词：

Diffuse large B-cell lymphoma; panobinostat; relapsed/refractory; genomic; DEACETYLASE INHIBITOR PANOBINOSTAT; HISTONE DEACETYLASES; RITUXIMAB; DISEASE; MULTICENTER; ROMIDEPSIN; MUTATION; LBH589; TRIAL; CHOP;

D O I：

10.1080/10428194.2018.1452208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

引用

页码：2904 / 2910

页数：7

共 50 条

[41] Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
Forero-Torres, Andres
Bartlett, Nancy
Beaven, Anne
Myint, Han
Nasta, Sunita
Northfelt, Donald W.
Whiting, Nancy C.
Drachman, Jonathan G.
LoBuglio, Albert F.
Moskowitz, Craig H.
LEUKEMIA & LYMPHOMA, 2013, 54 (02) : 277 - 283
[42] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
Saburi, Masuho
Sakata, Masanori
Kodama, Yousuke
Uraisami, Keiichi
Takata, Hiroyuki
Miyazaki, Yasuhiko
Wada, Junpei
Urabe, Shogo
Ohtsuka, Eiichi
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, : 201 - 204
[43] Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study
Chen, Guang-Liang
Xue, Kai
Zhang, Qunling
Xia, Zu-guang
Jin, Jia
Li, Ran
Liu, Yizhen
Lv, Fangfang
Hong, Xiaonan
Li, Xiaoqiu
Cao, Junning
CANCER MEDICINE, 2024, 13 (16):
[44] Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study
Yamshon, Samuel
Koff, Jean L.
Larson, Melissa C.
Kahl, Brad S.
Casulo, Carla
Lossos, Izidore S.
Haddadi, Sara
Stanchina, Michele
Chihara, Dai
Ayers, Amy
Habermann, Thomas M.
Wang, Yucai
Khurana, Arushi
Nowakowski, Grzegorz S.
Reicks, Tanner W.
Farooq, Umar
Link, Brian K.
Cohen, Jonathon B.
Martin, Peter
Li, Jia
Shewade, Ashwini
Batlevi, Connie Lee
Lo-Rossi, Andrea
Fox, David
Masaquel, Anthony
Mun, Yong
Cerhan, James R.
Flowers, Christopher R.
Maurer, Matthew J.
Nastoupil, Loretta J.
AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (04) : 606 - 615
[45] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
Saburi, Masuho
Sakata, Masanori
Kodama, Yousuke
Uraisami, Keiichi
Takata, Hiroyuki
Miyazaki, Yasuhiko
Wada, Junpei
Urabe, Shogo
Ohtsuka, Eiichi
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (03) : 201 - 204
[46] Therapeutic Options in Relapsed or Refractory Diffuse Large B-cell Lymphoma Part 2. Novel Therapeutic Strategies
Hernandez-Ilizaliturri, Francisco J.
Czuczman, Myron S.
ONCOLOGY-NEW YORK, 2009, 23 (07): : 610 - 615
[47] Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nedved, Adrienne
Maddocks, Kami
Nowakowski, Grzegorz S.
ONCOLOGIST, 2023, : 199 - 207
[48] Successful Treatment of Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type With Single-Agent Venetoclax
Walter, Harriet S.
Trethewey, Christopher S.
Ahearne, Matthew J.
Jackson, Ross
Jayne, Sandrine
Wagner, Simon D.
Saldanha, Gerald
Dyer, Martin J. S.
JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 5
[49] Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
Ip, Andrew
Mutebi, Alex
Wang, Tongsheng
Jun, Monika
Kalsekar, Anupama
Navarro, Fernando Rivas
Wang, Anthony
Kamalakar, Rajesh
Sacchi, Mariana
Elliott, Brian
ADVANCES IN THERAPY, 2024, 41 (03) : 1226 - 1244
[50] A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
Wagner-Johnston, Nina D.
Goy, Andre
Rodriguez, Maria A.
Ehmann, W. Christopher
Hamlin, Paul A.
Radford, John
Thieblemont, Catherine
Suh, Cheolwon
Sweetenham, John
Huang, Yifan
Sullivan, Sharon T.
Vandendries, Erik R.
Gisselbrecht, Christian
LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2863 - 2869

← 1 2 3 4 5 →